Literature DB >> 7692921

Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.

P Dreger1, P Marquardt, T Haferlach, S Jacobs, T Mülverstedt, V Eckstein, M Suttorp, H Löffler, W Müller-Ruchholtz, N Schmitz.   

Abstract

The mini-BEAM regimen (BCNU, etoposide, cytarabine, melphalan) and its modification 'Dexa-BEAM' are effective salvage protocols for relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Since many patients with relapsed lymphoma are eligible for high-dose chemotherapy with autologous stem cell rescue, we were interested in the suitability of these second line regimens for mobilising peripheral blood progenitor cells (PBPC). The kinetics of PBPC were studied in 15 patients treated with Dexa-BEAM and granulocyte colony-stimulating factor (G-CSF). Leukocytes started to rise from < 0.5 nL-1 on day 18 (16-22) after Dexa-BEAM, and exceeded 10 nL-1 on day 20 (18-28). Peripheral blood CFU-GM peaked on day 21 (19-28) and declined slowly thereafter; the median leukocyte count was 18.7 nL-1 (12.2-60) on the day of CFU-GM-peak. The maximum number of CFU-GM circulating in peripheral blood was inversely correlated to the duration of leukopenia after Dexa-BEAM. Measurement of CD34+ cells with the monoclonal antibody 8G12-PE (HPCA-2) predicted the number of CFU-GM precisely in both peripheral blood and leukapheresis products (r = 0.90-0.95). Two to six leukapheresis procedures yielded 6.39 x 10(8) mononuclear cells kg-1 (1.82-13.49) containing 44.4 x 10(4) CFU-GM kg-1 (2.2-213.8). Immunophenotypical analysis revealed that the percentage of CD19+ B cells was very low in all collection products (less than 1%). Nine patients were autografted with PBPC (15.4-213.8 x 10(4) CFU-GM kg-1) after myeloablative chemotherapy and experienced rapid and sustained engraftment (Platelets > 50 nL-1 on day +13 [9-22]). We conclude that PBPC can be mobilised effectively by Dexa-BEAM plus G-CSF. An adequate timing of PBPC collection (when the leukocyte count has exceeded 10 nL-1) and evaluation of the progenitor content of the leukapheresis products with 8G12-PE will allow to minimise the number of leukaphereses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692921      PMCID: PMC1968738          DOI: 10.1038/bjc.1993.460

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation.

Authors:  J G Bender; S F Williams; S Myers; D Nottleman; W J Lee; K L Unverzagt; D Walker; L B To; D E Van Epps
Journal:  Bone Marrow Transplant       Date:  1992-09       Impact factor: 5.483

2.  Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation.

Authors:  P Dreger; M Suttorp; T Haferlach; H Löffler; N Schmitz; W Schroyens
Journal:  Blood       Date:  1993-03-01       Impact factor: 22.113

3.  Cell-dose effect in circulating stem-cell autografting.

Authors:  L B To; P G Dyson; C A Juttner
Journal:  Lancet       Date:  1986-08-16       Impact factor: 79.321

4.  Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.

Authors:  R T Mitsuyasu; R E Champlin; R P Gale; W G Ho; C Lenarsky; D Winston; M Selch; R Elashoff; J V Giorgi; J Wells
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

5.  High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.

Authors:  N Schmitz; B Glass; P Dreger; T Haferlach; H A Horst; J Ollech-Chwoyka; M Suttorp; W Gassmann; H Löffler
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

6.  Increase in circulating stem cells following chemotherapy in man.

Authors:  C M Richman; R S Weiner; R A Yankee
Journal:  Blood       Date:  1976-06       Impact factor: 22.113

7.  Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation.

Authors:  J E Hardingham; D Kotasek; R E Sage; A Dobrovic; T Gooley; B M Dale
Journal:  Bone Marrow Transplant       Date:  1993-01       Impact factor: 5.483

8.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

Authors:  T Philip; J O Armitage; G Spitzer; F Chauvin; S Jagannath; J Y Cahn; P Colombat; A H Goldstone; N C Gorin; M Flesh
Journal:  N Engl J Med       Date:  1987-06-11       Impact factor: 91.245

9.  Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation.

Authors:  T Matsunaga; S Sakamaki; Y Kohgo; S Ohi; Y Hirayama; Y Niitsu
Journal:  Bone Marrow Transplant       Date:  1993-02       Impact factor: 5.483

10.  Phenotype of recovering lymphoid cell populations after marrow transplantation.

Authors:  K A Ault; J H Antin; D Ginsburg; S H Orkin; J M Rappeport; M L Keohan; P Martin; B R Smith
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

Authors:  J E Frampton; C R Lee; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

2.  High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.

Authors:  A K Blystad; H Holte; S Kvaløy; E Smeland; J Delabie; G Kvalheim
Journal:  Bone Marrow Transplant       Date:  2001-11       Impact factor: 5.483

3.  Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?

Authors:  P Dreger; N von Neuhoff; R Kuse; R Sonnen; B Glass; L Uharek; R Schoch; H Löffler; N Schmitz
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

4.  Optimal time to start peripheral blood stem cell collection in children with high-risk solid tumors.

Authors:  Ki Woong Sung; Hee Won Chueh; Na Hee Lee; Dong Hwan Kim; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo; Eun Suk Kang; Dae Won Kim
Journal:  J Korean Med Sci       Date:  2013-12-26       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.